Πρώτη αξιολόγηση της απόδοσης ενός εμφυτεύσιμου συστήματος συνεχούς παρακολούθησης της γλυκόζης για 180 ημέρες σε έναν κυρίως εφηβικό πληθυσμό με διαβήτη τύπου 1
από LMC Healthcare | Μάι 9, 2019 | Νέα |
This month, our newest publication is the full report of the Eversense study results. Eversense is the very nifty sensor that is implanted subcutaneously and provides continuous glucose monitoring to your phone for 6 months. Our results were in teenagers – the first pediatric study – and were the first to verify the full 180-day lifespan of this generation of the device, and the first in a Pediatric population. The results were presented by Dr. Alex Abitbol and Dr. Ronnie Aronson at the EASD and ADA sessions last year.
Read the publication here:
